Corinna Lathan
About Corinna Lathan
Independent director of Ekso Bionics Holdings since December 2021; age 57 as of March 18, 2025. Technology innovator with 20+ years in human-technology interfaces; former Board Chair/CEO of AnthroTronix, CEO of De Oro Devices (Dec 2023–Mar 2025), and current director at PTC, where she chairs the Cybersecurity Committee. Education: BA in Biopsychology & Mathematics (Swarthmore), MS Aeronautics & Astronautics (MIT), PhD Neuroscience (MIT) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| AnthroTronix | Board Chair & CEO | Through Jun 2022 | Led R&D in robotics/digital health/wearables |
| De Oro Devices | Chief Executive Officer | Dec 2023–Mar 2025 | Health technology business leadership |
| The Catholic University of America | Associate Professor, Biomedical Engineering | Prior role (dates not specified) | Academic leadership |
| University of Maryland, College Park | Adjunct Professor, Aerospace Engineering | Prior role (dates not specified) | Academic engagement |
External Roles
| Organization | Role | Start | Committees/Notes |
|---|---|---|---|
| PTC, Inc. (Nasdaq: PTC) | Director | Current (last 5 years) | Audit, Governance; Chair, Cybersecurity Committee |
| Engineers Without Borders USA | Director | Jan 2025 | Nonprofit governance |
Board Governance
- Committee assignments: Chair, Nominating & Governance; Member, Audit .
- Independence: Board determined independent (all nominees except CEO) .
- Attendance: Board met 10 times in 2024; each director attended ≥75% of Board/committee meetings; all current directors attended the 2024 AGM .
- Lead Independent Director: Served as Lead Independent Director from April/June 2023 until the 2024 Annual Meeting; role now held by Mary Ann Cloyd since June 2024 .
- Committee activity in 2024: Audit met 4 times; Compensation met 3 times; Nominating & Governance met 1 time .
Fixed Compensation
| Year (Service) | Cash Fees ($) | Equity Awards ($) | Options ($) | Total ($) |
|---|---|---|---|---|
| 2024 | 64,361 | 87,963 | — | 152,324 |
| 2023 | 65,804 | 92,327 | — | 146,172 |
Director Compensation Structure (current program):
- Annual retainers: Board member $35,000; Board chair $70,000; Lead independent director $25,000 .
- Committee retainers: Audit $7,500 member / $15,000 chair; Compensation $5,000 / $10,000; Nominating & Governance $5,000 / $10,000 .
Performance Compensation
| Element | Key Terms |
|---|---|
| Annual RSU grant | Approx. $100,000; number of RSUs based on 30-day average closing price; vests at earlier of next annual meeting or 1-year anniversary |
| RSUs outstanding (12/31/2024) | 78,217 RSUs |
Performance metrics available under the 2014 Plan (for performance awards; directors typically receive time-based RSUs):
| Metric Category | Examples |
|---|---|
| Financial | Revenue; EBITDA; EPS; Operating cash flow; Operating income; Profit before/after tax |
| Returns/Market | ROA; ROE; Return on sales; Total shareholder return; Market share |
| Operational/Strategic | Budget achievement; Productivity; Acquisitions/integration; Scientific/regulatory achievements; R&D milestones; Expense reduction/cost savings |
Note: No director-specific performance conditions disclosed; RSU vesting is time-based .
Other Directorships & Interlocks
| Company | Sector Relation to EKSO | Potential Interlock/Conflict |
|---|---|---|
| PTC, Inc. | Software/PLM/IoT/AR; not a direct EKSO competitor | No related-party transactions disclosed; governance/cyber expertise benefits EKSO |
| Engineers Without Borders USA | Nonprofit | None disclosed |
Expertise & Qualifications
- Deep technical expertise in human-technology interfaces for robotics/mobile platforms; extensive governance and risk oversight experience .
- Academic credentials and leadership across engineering and neuroscience .
- Cybersecurity oversight at PTC; audit and governance committee experience at EKSO and PTC .
Equity Ownership
| Holder | Beneficial Ownership (shares) | % of Outstanding | Notes |
|---|---|---|---|
| Corinna Lathan | 147,990 | ~0.5% (147,990 / 28,196,693) | No options disclosed; RSUs outstanding at 12/31/2024: 78,217 |
Policies affecting alignment:
- No hedging/monetization transactions permitted for directors/officers/employees/consultants .
- Clawback policy adopted Oct 2023 (covers incentive comp tied to financial reporting measures, including stock price/TSR) .
- No Rule 10b5-1 trading plans adopted by directors/officers as of disclosures .
Insider Filings
| Year | Section 16 Compliance Note |
|---|---|
| 2024 | One Form 4 reporting one transaction for Dr. Lathan was filed late due to administrative error |
| 2023 | One Form 4 reporting three transactions and one Form 4 reporting one transaction for Dr. Lathan were filed late due to administrative errors |
Say‑on‑Pay & Shareholder Feedback (Context)
| Proposal (2024 AGM, Jun 6, 2024) | For | Against | Abstain | Broker Non‑votes |
|---|---|---|---|---|
| Advisory vote on NEO compensation | 6,303,399 | 631,663 | 124,065 | 4,366,114 |
| Frequency of future advisory votes | 1-year: 6,840,255; 2-years: 25,427; 3-years: 125,746; Abstain: 67,699 |
Governance Assessment
-
Strengths:
- Independent director with chair role on Nominating & Governance and service on Audit; prior Lead Independent Director tenure enhances board independence and oversight .
- Cross-board cybersecurity leadership at PTC adds valuable risk oversight in a tech-heavy company; strong technical and academic background supports product/governance dialogue .
- Good engagement signals: Board met 10 times in 2024; directors met ≥75% attendance; presence at AGM .
-
Watchpoints / RED FLAGS:
- Late Section 16 filings in 2023–2024 for Dr. Lathan indicate administrative weaknesses; generally minor but track for recurrence .
- Concurrent CEO role at De Oro Devices through Mar 2025 could pose time‑allocation risks; no EKSO‑related transactions disclosed, but monitor for potential related‑party exposure if any dealings emerge .
- Broader company capital structure signals (reverse split authorization; inducement warrant issuance) increase dilution risk and investor sensitivity; governance must ensure shareholder alignment in equity grant practices .
No related-party transactions involving Dr. Lathan were disclosed; the only noted related‑party item pertains to Dr. Li and Angel Pond settlement in Feb 2023 ($325) .